These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 2455592

  • 1. Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B- and T-cell lymphomas.
    Basham TY, Palladino MA, Badger CC, Bernstein ID, Levy R, Merigan TC.
    Cancer Res; 1988 Aug 01; 48(15):4196-200. PubMed ID: 2455592
    [Abstract] [Full Text] [Related]

  • 2. Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma.
    Basham TY, Kaminski MS, Kitamura K, Levy R, Merigan TC.
    J Immunol; 1986 Nov 01; 137(9):3019-24. PubMed ID: 3760580
    [Abstract] [Full Text] [Related]

  • 3. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
    Iigo M, Sakurai M, Tamura T, Saijo N, Hoshi A.
    Cancer Res; 1988 Jan 15; 48(2):260-4. PubMed ID: 2446744
    [Abstract] [Full Text] [Related]

  • 4. Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.
    Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC.
    J Immunol; 1988 Oct 15; 141(8):2855-60. PubMed ID: 2971732
    [Abstract] [Full Text] [Related]

  • 5. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y, Morikage T, Hirata H, Sato M, Sakamoto K, Yano S.
    J Biol Response Mod; 1988 Aug 15; 7(4):371-83. PubMed ID: 3139841
    [Abstract] [Full Text] [Related]

  • 6. In vivo myelosuppression by combination interferon treatment: antagonism of MuIFN-gamma and MuIFN-beta myelosuppressive effects.
    Naldini A, Fleischmann WR.
    J Biol Response Mod; 1987 Oct 15; 6(5):546-55. PubMed ID: 3119781
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, Tso JY, Waldmann TA.
    Cancer Res; 2000 Dec 15; 60(24):6977-84. PubMed ID: 11156399
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW, Tso J, Kosteiny SA, Gansow OA, Nelson DL.
    Cancer Res; 1994 Aug 15; 54(16):4362-70. PubMed ID: 8044783
    [Abstract] [Full Text] [Related]

  • 12. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C, Brissinck J, Leo O, Moser M, Thielemans K.
    Cancer Res; 1994 Jun 01; 54(11):2973-8. PubMed ID: 8187084
    [Abstract] [Full Text] [Related]

  • 13. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 14. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 15. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M, Matsuzaki G, Yoshikai Y, Kobayashi N, Kurosawa S, Takimoto H, Nomoto K.
    Cancer Res; 1993 Jan 01; 53(1):106-11. PubMed ID: 8093229
    [Abstract] [Full Text] [Related]

  • 16. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
    Cameron RB, McIntosh JK, Rosenberg SA.
    Cancer Res; 1988 Oct 15; 48(20):5810-7. PubMed ID: 3262413
    [Abstract] [Full Text] [Related]

  • 17. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
    Berinstein N, Levy R.
    J Immunol; 1987 Aug 01; 139(3):971-6. PubMed ID: 3496394
    [Abstract] [Full Text] [Related]

  • 18. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H, Gavigan M, O'Malley J, Thompson D, Dadey B, Nussbaum-Blumenson A, Snider C, Rudnick S, Ferraresi R, Norred S.
    J Biol Response Mod; 1983 Aug 01; 2(6):499-515. PubMed ID: 6607323
    [Abstract] [Full Text] [Related]

  • 19. Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody.
    Badger CC, Krohn KA, Peterson AV, Shulman H, Bernstein ID.
    Cancer Res; 1985 Apr 01; 45(4):1536-44. PubMed ID: 3978621
    [Abstract] [Full Text] [Related]

  • 20. Effect of hyperthermia on the antiproliferative activities of murine alpha-, beta-, and gamma-interferon: differential enhancement of murine gamma-interferon.
    Fleischmann WR, Fleischmann CM, Gindhart TD.
    Cancer Res; 1986 Jan 01; 46(1):8-13. PubMed ID: 2998611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.